Intravenous immunoglobulin for the treatment of childhood encephalitis
Encephalitis is a syndrome of neurological dysfunction due to inflammation of the brain parenchyma, caused by an infection or an exaggerated host immune response, or both. Attenuation of brain inflammation through modulation of the immune response could improve patient outcomes. Biological agents su...
Hlavní autoři: | Iro, M, Martin, N, Absoud, M, Pollard, A |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Cochrane Collaboration
2017
|
Podobné jednotky
-
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial
Autor: Hill, M, a další
Vydáno: (2023) -
Childhood encephalitis in the United Kingdom - epidemiology, trends in hospital admissions and the role of intravenous immunoglobulin
Autor: Iro, M
Vydáno: (2018) -
Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
Autor: Iro, MA, a další
Vydáno: (2024) -
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial
Autor: Simon Nadel, a další
Vydáno: (2023-11-01) -
Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
Autor: Mildred A Iro, a další
Vydáno: (2024-04-01)